| Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly |
NCT05545800: Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy |
|
|
| Recruiting | 3 | 78 | RoW | metformin+empagliflozin+insulin glargine, IDegLira, premixed insulin analogues | Xiangya Hospital of Central South University | Type 2 Diabetes Mellitus | 06/24 | 06/24 | | |
TERA 305, NCT05504226: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin |
|
|
| Recruiting | 3 | 208 | RoW | Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet, Teneligliptin Placebo Oral Tablet | Handok Inc. | Type 2 Diabetes | 11/24 | 05/25 | | |
TERA 304, NCT05504239: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin |
|
|
| Recruiting | 3 | 228 | RoW | Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet, Teneligliptin Placebo Oral Tablet | Handok Inc. | Type 2 Diabetes | 11/24 | 03/25 | | |
NN9924-7663, NCT06083675: Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes |
|
|
| Withdrawn | 3 | 912 | Europe, US, RoW | Semaglutide, Empagliflozin, Metformin | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 01/25 | 05/27 | | |
NCT06140108: Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity |
|
|
| Completed | 2/3 | 70 | RoW | Empagliflozin 10 MG, EMPAA 10mg, MetFORMIN 500 Mg Oral Tablet, Glucophage 500mg | SINA Health Education and Welfare Trust | Polycystic Ovary Syndrome, Weight Gain, HbA1c | 03/24 | 03/24 | | |
